{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:19Z","timestamp":1790916979174,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01238-9","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:00:49Z","timestamp":1785330049000},"page":"775-784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-741X","authenticated-orcid":false,"given":"Mimma","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Incorvaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mayrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Niedersuess-Beke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Seront","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Stumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"17","key":"1238_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3068.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1238_CR2","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, de Mulder PH, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19(10):2638\u201346. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2638.","journal-title":"J Clin Oncol"},{"issue":"33","key":"1238_CR3","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","volume":"27","author":"M De Santis","year":"2009","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II\/III trial assessing gemcitabine\/ carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II\u2014results of EORTC study 30986. J Clin Oncol. 2009;27(33):5634\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.21.4924.","journal-title":"J Clin Oncol"},{"key":"1238_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","volume":"25","author":"E Grande","year":"2024","unstructured":"Grande E, Arranz JA, De Santis M, Powles T, Bellmunt J, Wang J, et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024;25:29\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(23)00540-5.","journal-title":"Lancet Oncol"},{"key":"1238_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Gakis G, Loriot Y, et al. ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35:485\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001.","journal-title":"Ann Oncol"},{"key":"1238_CR6","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: bladder cancer. Version 3.2025. Plymouth Meeting (PA): NCCN; 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed 20 Feb 2026."},{"key":"1238_CR7","unstructured":"European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer. Arnhem: EAU Guidelines Office; 2024. https:\/\/uroweb.org\/guidelines. Accessed 20 Feb 2026."},{"issue":"10","key":"1238_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"13","key":"1238_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"issue":"19","key":"1238_CR10","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Kalofonos H, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u2265 2 years of follow-up. J Clin Oncol. 2023;41(19):3486\u201392. https:\/\/doi.org\/10.1200\/JCO.22.01792.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 6","key":"1238_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1200\/JCO.2023.41.6_suppl.508","volume":"41","author":"SS Sridhar","year":"2023","unstructured":"Sridhar SS, Powles T, Gupta S, Caserta C, Valderrama BP, Gurney H, et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. J Clin Oncol. 2023;41(Suppl. 6):508. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.508.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1238_CR12","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Loriot Y, Balar AV, Necchi A, et al. Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"issue":"3","key":"1238_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06131-y","volume":"151","author":"K Schlack","year":"2025","unstructured":"Schlack K, Machtens S, Kubin T, Ruhnke M, Schulte C, Eisen A, et al. Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study. J Cancer Res Clin Oncol. 2025;151(3):100. https:\/\/doi.org\/10.1007\/s00432-025-06131-y.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1238_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/14796694.2024.2445498","volume":"21","author":"A Hasaligil","year":"2025","unstructured":"Hasaligil A, Munro V, Strunz-McKendry T, Wang-Silvanto J, Milloy N, Unsworth M, et al. Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain. Future Oncol. 2025;21(5):569\u201378. https:\/\/doi.org\/10.1080\/14796694.2024.2445498.","journal-title":"Future Oncol"},{"issue":"5","key":"1238_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.9417","volume":"7","author":"VM Thomas","year":"2024","unstructured":"Thomas VM, Jo Y, Tripathi N, Tsao CK, Patel VG, Rosenberg JE, et al. Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US. JAMA Netw Open. 2024;7(5):e249417. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.9417.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1238_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102238","volume":"22","author":"P Grivas","year":"2024","unstructured":"Grivas P, Barata P, Moon H, Kearney M, Mahmoudpour SH, Hasaligil A, et al. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study. Clin Genitourin Cancer. 2024;22(6):102238. https:\/\/doi.org\/10.1016\/j.clgc.2024.102238.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"1238_CR17","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.3390\/curroncol31090420","volume":"31","author":"HH Moon","year":"2024","unstructured":"Moon HH, Kearney M, Mahmoudpour SH, Hasaligil A, Barata P, Grivas P, et al. Real-world treatment patterns, sequencing, and outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in the United States. Curr Oncol. 2024;31(9):5662\u201376. https:\/\/doi.org\/10.3390\/curroncol31090420.","journal-title":"Curr Oncol"},{"issue":"5","key":"1238_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","volume":"21","author":"DR Bakaloudi","year":"2023","unstructured":"Bakaloudi DR, Talukder R, Lin GI, Bilen MA, Zhang T, Agarwal N, et al. Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \u201creal world\u201d experience. Clin Genitourin Cancer. 2023;21(5):584\u201393. https:\/\/doi.org\/10.1016\/j.clgc.2023.06.008.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"1238_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/iju.15473","volume":"31","author":"E Kikuchi","year":"2024","unstructured":"Kikuchi E, Hayakawa N, Nakayama M, Matsumoto K, Kondo T, Miyake M, et al. J-AVENUE: a retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan. Int J Urol. 2024;31(8):859\u201367. https:\/\/doi.org\/10.1111\/iju.15473.","journal-title":"Int J Urol"},{"key":"1238_CR20","doi-asserted-by":"publisher","first-page":"1403120","DOI":"10.3389\/fonc.2024.1403120","volume":"14","author":"SH Park","year":"2024","unstructured":"Park SH, Shin SJ, Rha SY, Lee JL, Jeong IG, Kim HS, et al. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program. Front Oncol. 2024;14:1403120. https:\/\/doi.org\/10.3389\/fonc.2024.1403120.","journal-title":"Front Oncol"},{"issue":"2","key":"1238_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","volume":"8","author":"P Barthelemy","year":"2025","unstructured":"Barthelemy P, Thibault C, Flechon A, Houede N, Oudard S, Culine S, et al. Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment. Eur Urol Oncol. 2025;8(2):407\u201316. https:\/\/doi.org\/10.1016\/j.euo.2024.09.014.","journal-title":"Eur Urol Oncol."},{"key":"1238_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100068","volume":"5","author":"L Antonuzzo","year":"2024","unstructured":"Antonuzzo L, Maruzzo M, De Giorgi U, Buti S, Massari F, Santoni M, et al. READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma. ESMO Real World Data Digit Oncol. 2024;5:100068. https:\/\/doi.org\/10.1016\/j.esmorw.2024.100068.","journal-title":"ESMO Real World Data Digit Oncol."},{"issue":"12","key":"1238_CR23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"issue":"21","key":"1238_CR24","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2308849.","journal-title":"N Engl J Med"},{"issue":"6","key":"1238_CR25","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34040","volume":"128","author":"VS Koshkin","year":"2022","unstructured":"Koshkin VS, Henderson N, James M, Agarwal N, Grivas P, Flaig TW, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022;128(6):1194\u2013205. https:\/\/doi.org\/10.1002\/cncr.34040.","journal-title":"Cancer"},{"issue":"6","key":"1238_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s11523-024-01131-6","volume":"19","author":"O Fiala","year":"2024","unstructured":"Fiala O, Massari F, Basso U, Buti S, Santoni M, Maruzzo M, et al. Enfortumab vedotin following platinum chemotherapy and avelumab maintenance in patients with metastatic urothelial carcinoma: a retrospective data from the ARON-2EVsStudy. Target Oncol. 2024;19(6):905\u201315. https:\/\/doi.org\/10.1007\/s11523-024-01131-6.","journal-title":"Target Oncol"},{"issue":"4","key":"1238_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70479","volume":"14","author":"M Rizzo","year":"2025","unstructured":"Rizzo M, Morelli F, \u00dcr\u00fcn Y, Fiala O, Basso U, Buti S, et al. Real-life impact of enfortumab vedotin or chemotherapy in the sequential treatment of advanced urothelial carcinoma: the ARON-2 retrospective experience. Cancer Med. 2025;14(4):e70479. https:\/\/doi.org\/10.1002\/cam4.70479.","journal-title":"Cancer Med"},{"issue":"2","key":"1238_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10585-025-10342-8","volume":"42","author":"O Fiala","year":"2025","unstructured":"Fiala O, Buti S, Fujita K, Massari F, Basso U, Maruzzo M, et al. Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study. Clin Exp Metastasis. 2025;42(2):18. https:\/\/doi.org\/10.1007\/s10585-025-10342-8.","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"1238_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00432-024-05729-0","volume":"150","author":"Y Hirasawa","year":"2024","unstructured":"Hirasawa Y, Adachi T, Hashimoto T, Yoshida T, Kato M, Nishiyama H, et al. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan. J Cancer Res Clin Oncol. 2024;150(4):182. https:\/\/doi.org\/10.1007\/s00432-024-05729-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"1238_CR30","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173\u201381. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3173.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1238_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jnci\/djad232","volume":"116","author":"S Gupta","year":"2024","unstructured":"Gupta S, Andreev-Drakhlin A, Fajardo O, Sonpavde G, Powles T, Balar AV, et al. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment. J Natl Cancer Inst. 2024;116(4):547\u201354. https:\/\/doi.org\/10.1093\/jnci\/djad232.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1238_CR32","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"issue":"8","key":"1238_CR33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-3342","volume":"29","author":"N Kl\u00fcmper","year":"2023","unstructured":"Kl\u00fcmper N, Ralser DJ, Ellinger J, Arbinger K, Helmbold P, Kristiansen G, et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin Cancer Res. 2023;29(8):1496\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3342.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1238_CR34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"JE Rosenberg","year":"2020","unstructured":"Rosenberg JE, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041\u20139. https:\/\/doi.org\/10.1200\/JCO.19.02044.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1238_CR35","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-23-0315","volume":"29","author":"DH Aggen","year":"2023","unstructured":"Aggen DH, Chu CE, Rosenberg JE. Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance. Clin Cancer Res. 2023;29(8):1377\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0315.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1238_CR36","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.02062","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S, Ralser DJ, Ellinger J, Kristiansen G, et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J Clin Oncol. 2024;42(20):2446\u201355. https:\/\/doi.org\/10.1200\/JCO.23.02062.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01238-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01238-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:45Z","timestamp":1790916705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01238-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01238-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mimma Rizzo has received honoraria as a speaker\/consultant by MSD, Eisai, BMS, Ipsen, Merck Serono, Astellas, and Astrazeneca outside the submitted work. Ond\u0159ej Fiala received honoraria from Roche, Janssen, GSK, MSD, BMS, Pierre Fabre, and Pfizer for consultations and lectures unrelated to this project. Javier Molina-Cerrillo declares consultant, advisory, or speaker roles for Ipsen, Roche, Pfizer, Sanofi, Janssen, and BMS and has received research grants from Pfizer, Ipsen, and Roche. All are unrelated to this study. Francesco Massari has received research support and\/or honoraria from Advanced Accelerator Applications, Astellas, Astra Zeneca, Bayer, BMS, Janssen, Ipsen, Merck, MSD, and Pfizer outside the submitted work. Fernando Sabino Marques Monteiro has received research support by MSD and Foundation Medicine, honoraria from Janssen, Ipsen, BMS, Novartis, AstraZeneca, Bayer, Astellas, and MSD, travel expenses by Novartis, Bayer, ADIUM, Merck, and Johnson & Johnson, a consulting or advisory role from Novartis, and ownership from BIO, Brazilian Information Oncology. All are unrelated to this study. Andrey Soares has received honoraria from Janssen, Pfizer, Bayer, Merck Serono, and Novartis, a consulting or advisory role from Janssen, Bayer, AstraZeneca, MSD, Pfizer, and Novartis, research funding from Bristol-Myers Squibb (institution), Astellas (institution), AstraZeneca (institution), travel, accommodation, and expenses from Bayer, Janssen, MSD, Merck Serono, and Adium, and ownership from BIO, Brazilian Information Oncology. All are unrelated to this study. Thomas B\u00fcttner has received speakers\u2019 honoraria from Astellas and travel fees from Ipsen and MSD. All are unrelated to this study. Enrique Grande has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adacap, Amgen, Angelini, Astellas, AstraZeneca, Bayer, Blueprint, BMS, Caris Life Sciences, Celgene, Clovis Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, Ipsen, ITM-Radiopharma, Janssen, Lexicon, Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany; Merck & Co., Inc., Kenilworth, NJ, USA; NanoString Technologies; Natera; Novartis, OncoDNA (Biosequence), Palex, PharmaMar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, and Thermo Fisher Scientific, and has received research grants from Pfizer, AstraZeneca, Astellas, the healthcare business of Merck KGaA, Darmstadt, Germany, and Lexicon Pharmaceuticals. All are unrelated to this study. Matteo Santoni has received research support and honoraria from Janssen, Bristol Myers Squibb, Ipsen, MSD, Astellas and Bayer. Sebastiano Buti, Lorena Incorvaia, Maria T. Bourlon, Wataru Fukuokaya, Fumihiko Urabe, Se Hoon Park, Karl Mayrhofer, Renate Pichler, Dora Niedersuess-Beke, Tarek Taha, Aristotelis Bamias, Emmanuel Seront, Daniele Santini, Luciano Stumbo, and Alejo Rodriguez-Vida have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved on 28 September, 2023 by the ethical committee of the coordinating center (Marche Region, Italy, no. 2022 39\/7875) and by the institutional review boards of the participating centers. The study was conducted in accordance with Good Clinical Practice and the International Ethical Guidelines for Biomedical Research.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent with a subsequent analysis of the follow-up data was obtained from all participants.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data and materials supporting the findings of this study are available from the last author upon reasonable request.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: MR, SB, EG, MS. Methodology: MR, MS. Formal analysis: MS. Data curation: MS. Writing (original draft): MR, SB, EG, MS. Writing (review and editing): all authors. Supervision: MR, SB, EG, MS.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}